ARTICLE | Clinical News
Symbicort budesonide/formoterol: Phase III data
September 5, 2016 7:00 AM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Symbicort budesonide/formoterol Business: Inflammation Molecular target: Corticoid receptors; Adrenergic receptor beta 2 ( ADRB2) Descript...